<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23451166</article-id><article-id pub-id-type="pmc">3581561</article-id><article-id pub-id-type="publisher-id">PONE-D-12-30924</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0057143</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Anatomy and Physiology</subject><subj-group><subject>Endocrine System</subject><subj-group><subject>Diabetic Endocrinology</subject></subj-group></subj-group></subj-group><subj-group><subject>Cardiovascular</subject><subj-group><subject>Hypertension</subject></subj-group></subj-group><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Clinical Trials</subject></subj-group></subj-group><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Test Evaluation</subject></subj-group></subj-group><subj-group><subject>Endocrinology</subject><subj-group><subject>Diabetic Endocrinology</subject><subj-group><subject>Diabetes Mellitus Type 2</subject></subj-group></subj-group></subj-group><subj-group><subject>Non-Clinical Medicine</subject><subj-group><subject>Health Care Policy</subject><subj-group><subject>Health Risk Analysis</subject><subject>Screening Guidelines</subject><subject>Treatment Guidelines</subject></subj-group></subj-group></subj-group><subj-group><subject>Nutrition</subject><subj-group><subject>Obesity</subject></subj-group></subj-group><subj-group><subject>Public Health</subject><subj-group><subject>Behavioral and Social Aspects of Health</subject><subject>Health Screening</subject><subject>Preventive Medicine</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Importance of Weight Loss Maintenance and Risk Prediction in the Prevention of Type 2 Diabetes: Analysis of European Diabetes Prevention Study RCT</article-title><alt-title alt-title-type="running-head">European Diabetes Prevention Study</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Penn</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lindstr&#x000f6;m</surname><given-names>Jaana</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>den Boer</surname><given-names>Annemieke Th.</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Blaak</surname><given-names>Ellen</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Johan G.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Feskens</surname><given-names>Edith</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ilanne-Parikka</surname><given-names>Pirjo</given-names></name><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kein&#x000e4;nen-Kiukaanniemi</surname><given-names>Sirkka M.</given-names></name><xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff9">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mathers</surname><given-names>John C.</given-names></name><xref ref-type="aff" rid="aff10">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Uusitupa</surname><given-names>Matti</given-names></name><xref ref-type="aff" rid="aff11">
<sup>11</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tuomilehto</surname><given-names>Jaakko</given-names></name><xref ref-type="aff" rid="aff12">
<sup>12</sup>
</xref><xref ref-type="aff" rid="aff13">
<sup>13</sup>
</xref><xref ref-type="aff" rid="aff14">
<sup>14</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Chronic Disease Prevention, Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Human NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Central Hospital and Folkh&#x000e4;lsan Research Center, Helsinki, Finland</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>The Diabetes Center, Finnish Diabetes Association, Tampere, Finland</addr-line>
</aff><aff id="aff8">
<label>8</label>
<addr-line>Institute of Health Sciences (General Practice), University of Oulu and Central Hospital, Oulu, Finland</addr-line>
</aff><aff id="aff9">
<label>9</label>
<addr-line>Institute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne, United Kingdom</addr-line>
</aff><aff id="aff10">
<label>10</label>
<addr-line>Human Nutrition Research Centre, Institute for Ageing and Health, Newcastle University, Newcastle on Tyne, United Kingdom</addr-line>
</aff><aff id="aff11">
<label>11</label>
<addr-line>Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland</addr-line>
</aff><aff id="aff12">
<label>12</label>
<addr-line>South Ostrobothnia Central Hospital, Sein&#x000e4;joki, Finland</addr-line>
</aff><aff id="aff13">
<label>13</label>
<addr-line>Hospital Universitario La Paz, Madrid, Spain</addr-line>
</aff><aff id="aff14">
<label>14</label>
<addr-line>Centre for Vascular Prevention, Danube-University, Krems, Austria</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Casarini</surname><given-names>Dulce Elena</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Federal University of S&#x000e3;o Paulo (UNIFESP), Escola Paulista de Medicina, Brazil</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>linda.penn@ncl.ac.uk</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have the following interests. M. Walker has been paid for consultancy work by Sanofi. JL has been paid for lectures by MSD and Ely Lilly Finland and paid for travel and meeting expenses by Novo Nordisk. Following completion of: 1 the EDIPS-Newcastle study, LP, M. White, JCM, and M. Walker (with full agreement of the Wellcome Trust); 2 the DPS JL; and 3 the SLIM study EB A-dB; have supplied expertise, data and study samples to Tethys Bioscience, 5858 Horton St, Suite 280 Emeryville, CA 94608. Newcastle University, THL Finland, and Maastricht University received remuneration from Tethys bioscience as well as additional sample analysis data. These resources did not contribute to completion of the submitted work. There are no other relationships or activities that could appear to have influenced the submitted work.</p></fn><fn fn-type="con"><p>Contributed to revisions, commented on the manuscript, and approved the final version prior to publication: LP M. White JL A-dB EB JGE EF PIP SKK M. Walker JCM MU JT. Provided clinical advice and support during the conduct of EDIPS-Newcastle: M. Walker. Secured funding for the DPS study cohort: JT MU. Secured funding for EDIPS-Newcastle: M. White JCM. Secured funding for SLIM : EB EF. Secured funding for the EDIPS collaboration, EU Concerted Action (CA) Contract N&#x000b0; BMH4-CT98-3759 (DG 12-SSMI): EB EF. Guarantors for this work: LP M. White JL A-dB EB JGE EF PIP SKK M. Walker JCM MU JT. Conceived and designed the experiments: JT MU M. White JCM EB EF. Performed the experiments: JL PIP JGE LP A-dB SKK. Analyzed the data: LP. Wrote the paper: LP.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>25</day><month>2</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>e57143</elocation-id><history><date date-type="received"><day>27</day><month>9</month><year>2012</year></date><date date-type="accepted"><day>17</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Penn et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Penn et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Prevalence of type 2 diabetes (T2D) is increasing worldwide. T2D prevention by lifestyle intervention is effective. Pragmatic scalable interventions are needed, with evidence to efficiently target and monitor such interventions. We report pooled analyses of data from three European trial cohorts: to analyse T2D incidence, sustained weight loss and utility of risk predictors.</p></sec><sec><title>Methods</title><p>We analysed data on 749 adults with impaired glucose tolerance (278 men and 471 women, mean age 56 years, mean BMI 31 kgm<sup>&#x02212;2</sup>) recruited between 1993 and 2003, and randomised to intensive lifestyle intervention (I) or lifestyle advice control (C). The intervention aimed to increase physical activity, modify diet, and promote weight loss&#x02265;5%. Using Cox-regression survival analysis, we assessed T2D incidence and the impact on T2D incidence of sustained weight loss, and of baseline cut-point values of FINDRISC score, fasting plasma glucose (FPG), and HbA<sub>1c</sub>.</p></sec><sec><title>Results</title><p>Mean follow-up duration was 3.1 years. T2D was diagnosed in 139 participants (I&#x0200a;=&#x0200a;45/379, C&#x0200a;=&#x0200a;94/370). Cumulative T2D incidence was 57% lower in the intervention compared with the control group (HR 0.42 (95% CI 0.29 to 0.60) P&#x0003c;0.001). Participants with &#x02265;5% weight loss at one year had 65% lower T2D incidence (HR 0.35 (95% CI 0.22 to 0.56) P&#x0003c;0.001); maintaining &#x02265;5% weight loss for two and three years further reduced T2D incidence. Recommended cut-points to identify those at high risk for T2D would have identified different proportions of European Diabetes Prevention Study (EDIPS) participants with similar hazard-ratios for intervention effect.</p></sec><sec><title>Conclusions</title><p>Pooled analysis of EDIPS trial data reinforces evidence for T2D prevention by lifestyle intervention. Analysis showed the preventive effect of &#x02265;5% weight loss, especially if maintained long term, which has utility for intervention monitoring. Analysis of proposed cut-points demonstrates difficulties in balancing risk and benefit, to efficiently target interventions and suggests evidence is needed to define clinical policy.</p></sec><sec><title>Trial registrations</title><p>The Finnish Diabetes Prevention study, Helsinki, Finland: ClinicalTrials.gov; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00518167?term=NCT00518167&#x00026;rank=1">NCT00518167</ext-link> The SLIM diabetes prevention study, Maastricht, The Netherlands: Clinical Trials.gov; <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT00381186?term=NCT00381186&#x00026;rank=1">NCT00381186</ext-link> The EDIPS-Newcastle diabetes prevention study, Newcastle upon Tyne, UK: International Standard Randomised Controlled Trial Number; <ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN15670600">ISRCTN15670600</ext-link>.</p></sec></abstract><funding-group><funding-statement>The EDIPS collaboration was funded by European Union Concerted Action (CA) Contract N&#x000b0; BMH4-CT98-3759 (DG 12-SSMI). The Diabetes Prevention Study was financially supported by the Academy of Finland (grants 8473/2298, 40758/5767, 38387/54175, 128315, and 129330), Ministry of Education, Novo Nordisk Foundation, Yrj&#x000f6; Jahnsson Foundation, Juho Vainio Foundation, Finnish Diabetes Research Foundation, Finnish Foundation for Cardiovascular Research, Unilever, and Competitive Research Funding from Tampere, Kuopio, and Oulu University Hospitals. EDIPS-Newcastle was funded by the Wellcome Trust (Grant No. 057146/Z/99/Z). The Study on Lifestyle Intervention and Impaired Glucose Tolerance Maastricht was supported by grants from the Dutch Diabetes Research Foundation (DFN 98.901, 2000.00.020 and 2007.15.002), the Netherlands Organization for Health Research and Development (ZonMW 940-35-034) and the Netherlands Organization for Scientific Research (NWO 2200.0139). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.</funding-statement></funding-group><counts><page-count count="11"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Diabetes is predicted to affect 552 million people globally by 2030. <xref rid="pone.0057143-InternationalDiabetes1" ref-type="bibr">[1]</xref> Type 2 diabetes (T2D) accounts for 90% of cases, resulting in substantial disability, premature mortality, and healthcare costs, <xref rid="pone.0057143-InternationalDiabetes1" ref-type="bibr">[1]</xref> and its prevention is an important public health challenge. Genetic predisposition contributes to T2D risk, but disease development is strongly linked to excess body weight and lifestyle factors including diet and inactivity. <xref rid="pone.0057143-InternationalDiabetes1" ref-type="bibr">[1]</xref> Both population level interventions to address obesity prevalence and interventions targeting individuals at high-risk of T2D are needed. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref>&#x02013;<xref rid="pone.0057143-Chatterton1" ref-type="bibr">[4]</xref> Impaired glucose tolerance (IGT) is a precursor of T2D that identifies individuals at high-risk <xref rid="pone.0057143-InternationalDiabetes1" ref-type="bibr">[1]</xref>.</p><p>The Finnish Diabetes Prevention Study (DPS) randomised controlled trial (RCT) demonstrated the efficacy of lifestyle intervention to prevent T2D in adults with IGT. <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref> Subsequent RCTs have demonstrated efficacy in other populations. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057143-Gillies1" ref-type="bibr">[6]</xref> The European Diabetes Prevention Study (EDIPS) collaboration applied the DPS protocol in other European countries. The EDIPS trial cohorts comprised the DPS study in Finland; <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref> the SLIM study in Maastricht, The Netherlands; <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref> and the EDIPS-Newcastle study in Newcastle upon Tyne, UK. <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref> All three EDIPS cohorts used a common protocol with similar intervention goals and study design, although some variability in local intervention delivery was permitted to enhance cultural acceptability. Details of the individual RCTs contributing to the pooled EDIPS data-set have been published <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref>.</p><p>A vital prerequisite in achieving reduction in T2D globally is to develop scalable, transferrable and cost-effective T2D prevention interventions that can be delivered in routine health care. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057143-Uusitupa1" ref-type="bibr">[9]</xref> The Finnish Development Programme for the Prevention and Care of Diabetes (DEHKO) and associated T2D prevention plan (FIN-D2D) is leading the way. <xref rid="pone.0057143-TheFinnishDiabetes1" ref-type="bibr">[10]</xref>, <xref rid="pone.0057143-Saaristo1" ref-type="bibr">[11]</xref>. The UK National Institute for Health and Clinical Excellence (NICE) has published guidance for &#x02018;Preventing type 2 diabetes: risk identification and interventions for individuals at high-risk&#x02019;. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057143-Chatterton1" ref-type="bibr">[4]</xref> The EDIPS RCTs recruited adults with IGT, but measuring glucose tolerance is impractical and too costly for large scale screening. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> Instead, translational studies have used prospective risk scores, such as the Finnish Diabetes Risk Score (FINDRISC), <xref rid="pone.0057143-Lindstrom1" ref-type="bibr">[12]</xref> to identify high-risk individuals. However risk scores are population specific, provide valid individual risk estimates only when all data items are available and accurate, and cannot diagnose T2D. The NICE Programme Development Group for T2D prevention has advocated a two-stage screening strategy, using a risk score followed by a blood test for fasting plasma glucose (FPG) or glycated haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>), to confirm high-risk. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> This is a pragmatic strategy, but RCT evidence for effective and sustained T2D prevention <xref rid="pone.0057143-Diabetes1" ref-type="bibr">[13]</xref>, <xref rid="pone.0057143-Lindstrm1" ref-type="bibr">[14]</xref> is derived from at-risk populations identified by IGT and extrapolation to other high risk groups may not be warranted. In addition, many translational studies use weight loss at one year follow-up as the primary outcome. <xref rid="pone.0057143-Hamman1" ref-type="bibr">[15]</xref> The effect of achieving a weight loss goal at Year 1, and subsequent maintenance, has not been demonstrated. Percentage weight loss provides an easily-measured self-regulation goal for intervention participants <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> and the number of participants who achieve a pre-determined percentage weight loss could offer a useful key performance indicator for intervention monitoring.</p><p>The EDIPS RCTs aimed to evaluate the efficacy of similar lifestyle intervention in three European populations. In this paper, we report pooled analysis of data from the EDIPS cohorts. Weight loss &#x02265;5% was an intervention goal <xref rid="pone.0057143-Lindstrm2" ref-type="bibr">[16]</xref> and, in this paper, we assessed the impact of sustained weight loss on T2D incidence. In addition, to inform future research and policy, we assessed the utility of alternative risk identification parameters and different cut point values in predicting outcomes in the EDIPS cohorts.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref ref-type="supplementary-material" rid="pone.0057143.s001">Checklist S1</xref> and <xref ref-type="supplementary-material" rid="pone.0057143.s002">Protocol S1</xref>.</p><sec id="s2a"><title>Ethics Statement</title><p>Ethical approvals were given for the DPS by the ethics committee of the National Public Health Institute, Helsinki, Finland; for the SLIM study by the Medical Ethical Review Committee of Maastricht University; and for EDIPS-Newcastle by the Newcastle and North Tyneside NHS research ethics committee. All participants gave their written informed consent before starting the study.</p></sec><sec id="s2b"><title>Trial Design</title><p>Details of the EDIPS protocol were similar in each country, have been published for each trial cohort <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref> and are described briefly here.</p></sec><sec id="s2c"><title>Randomisation and Masking</title><p>Participants were allocated at random in a 1&#x02236;1 ratio to an intensive lifestyle intervention to promote increased physical activity and dietary modification or to a minimal lifestyle advice control group. For the DPS and EDIPS-Newcastle (but not SLIM) the randomisation lists were generated and supplied by the coordinating centre in Helsinki and staff who made baseline measurements had no access to the randomisation lists. Neither staff delivering the intervention nor participants were masked to the study arm.</p></sec><sec id="s2d"><title>Follow-up</title><p>Participants received a clinical assessment, including an Oral Glucose Tolerance Test (OGTT), anthropometric and blood biochemistry measurements, at baseline and annually thereafter. In addition they were asked to complete physical activity and dietary intake diaries. Measurement details, timelines and locations have been published. <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref>, <xref rid="pone.0057143-Roumen2" ref-type="bibr">[17]</xref> In March 2000, independent statistical analysis of the DPS data led to the end-point committee&#x02019;s decision to end the DPS trial. Some participants completed six years in the study <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>.</p></sec><sec id="s2e"><title>Participants</title><p>We included adults over 40 years with BMI&#x02265;25 kgm<sup>&#x02212;2</sup> (or family history of T2D in the SLIM study) and with IGT, defined as plasma glucose concentration 7&#x000b7;8 to 11&#x000b7;0 mmoll<sup>&#x02212;1</sup> (140 to 199 mg/dl) two hours after a standard fasting Oral Glucose Tolerance Test (OGTT) (glucose load 75 g). <xref rid="pone.0057143-World1" ref-type="bibr">[18]</xref> Exclusion criteria were diagnosis of T2D, chronic illness making participation in moderate physical activity impossible and medication (e.g. corticosteroids) that would compromise the intervention.</p></sec><sec id="s2f"><title>Interventions</title><p>Intervention goals were based on a common protocol and comprised: weight reduction &#x02265;5%, moderate physical activity for at least 30 minutes per day or equivalent (assessed as at least 30 minutes at level 5 MET/hours) and improved dietary quality, with increased fibre, reduced fat and reduced saturated fat intake. The DPS and EDIPS-Newcastle goals for fat intake were &#x0003c;30% total fat and &#x0003c;10% saturated fat, whilst the SLIM study goals were in accordance with the Dutch guidelines (Dutch Nutrition Council) that advised 30 to 35% total fat intake with &#x0003c;10% saturated fat <xref rid="pone.0057143-NetherlandsNutrition1" ref-type="bibr">[19]</xref>.</p><p>Intervention delivery centred on individual counselling, including motivational interviewing. <xref rid="pone.0057143-Rollnick1" ref-type="bibr">[20]</xref> Physical activity and food diaries, completed quarterly, facilitated personalised advice delivered by trained health professionals. Supervised physical activity sessions and access to leisure facilities were promoted.</p></sec><sec id="s2g"><title>Control Condition</title><p>Control group participants were given brief written and verbal information about a healthy diet and the benefits of physical activity.</p></sec><sec id="s2h"><title>Outcomes</title><p>The primary outcome was impact of lifestyle intervention on T2D incidence. Diagnosis of T2D was determined at annual follow-up using a standard OGTT with 2 hour venous plasma glucose &#x02265;11&#x000b7;1 mmoll<sup>&#x02212;1</sup> or FPG&#x02265;7&#x000b7;8 mmoll<sup>&#x02212;1</sup> in accordance with WHO criteria. <xref rid="pone.0057143-World1" ref-type="bibr">[18]</xref> In the DPS and EDIPS-Newcastle cohorts, a repeat measure confirmed the diagnosis and was a study end-point. In the SLIM cohort, diabetes diagnosis was based on a single OGTT. Secondary outcomes were weight loss, increased physical activity and improved dietary quality.</p><p>Sample size was determined for the DPS with 80% power and 95% significance to detect 30% reduction of T2D incidence in the intervention group compared with the control group. This calculation was based on the assumption that 28% of adults with IGT would progress to T2D in five years. The DPS, EDIPS-Newcastle and SLIM cohorts contributed to a planned total of 750 European participants <xref rid="pone.0057143-Eriksson1" ref-type="bibr">[21]</xref>.</p></sec><sec id="s2i"><title>Data Analysis</title><p>For analysis of the pooled EDIPS data-set we used SPSS (IBM SPSS inc. Version 17). We used independent t-tests and Chi-squared tests to compare variables at baseline and Cox-regression survival analysis to assess risk of developing T2D, with T2D incidence as the explanatory variable controlling for trial cohort (Finland, The Netherlands, and The UK). For pooled analysis of the main trial outcome, we used RevMan (The Cochrane Collaboration Review Manager 5.1) to conduct meta-analysis assessing risk ratios using Mantel-Haenszel, random effects and Tau<sup>2</sup> variance measure.</p><p>The EDIPS data-set includes cases with baseline FPG&#x02265;7&#x000b7;0 mmoll <sup>&#x02212;1</sup> or HbA1c &#x02265;6&#x000b7;5%. In 2012, these values would be in the diabetic range due to recent changes in WHO diagnostic criteria. <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref>, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref> We therefore analysed a sub-set of the EDIPS data with these cases removed as a sensitivity analysis.</p><p>For explanatory analysis of weight loss maintenance, we pooled intervention and control group data. In separate analyses, we compared those who achieved &#x02265;5% weight loss at 12 months, those who achieved this goal at 12 months and maintained it at 24 months, and those who achieved this goal at 12 months, maintained it at 24 months and again at 36 months, with those who did not achieve these goals.</p><p>We analysed values of FINDRISC score, <xref rid="pone.0057143-Lindstrom1" ref-type="bibr">[12]</xref> FPG and HbA1c at baseline in relation to EDIPS outcomes. We used Cox-regression to analyse the effect of intervention on risk of developing T2D in EDIPS sub-sets defined by FPG and HbA1c cut-points recommended by NICE <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref> and the American Diabetes Association (ADA) <xref rid="pone.0057143-AmericanDiabetes1" ref-type="bibr">[24]</xref> and, for FPG, recommended by WHO <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref> (the WHO expert group concluded that there was insufficient evidence to recommend HbA1c cut-points for non-diabetic hyperglycaemia <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref>), as well as combinations of risk score and blood tests ranges.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Incidence of T2D</title><p>In the three European Diabetes Prevention Study (EDIPS) cohorts we recruited a total of 771 participants and followed them up for a mean duration of 3&#x000b7;1 years (maximum 6 years). <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref> For the analyses presented here, we included 749 (DPS n&#x0200a;=&#x0200a;522, SLIM n&#x0200a;=&#x0200a;125, and EDIPS-Newcastle n&#x0200a;=&#x0200a;102) with IGT at baseline (22 participants from the SLIM study with 2 hour plasma glucose value &#x0003e;11&#x000b7;0 moll<sup>&#x02212;1</sup> were excluded). Details of the recruitment dates, randomisation and trial progression are shown in <xref ref-type="fig" rid="pone-0057143-g001">Figure 1</xref>. Baseline characteristics included mean (SD) age 55&#x000b7;6 (8&#x000b7;1) years, BMI 31&#x000b7;2 (4&#x000b7;9) kgm<sup>&#x02212;2</sup>, and FINDRISC score 14&#x000b7;0 (4&#x000b7;2). There were no statistical differences in any of the baseline measures between intervention and control groups (<xref ref-type="table" rid="pone-0057143-t001">Table 1</xref>). T2D was diagnosed in 139 participants (I&#x0200a;=&#x0200a;45, C&#x0200a;=&#x0200a;94). The absolute incidence of T2D was 38&#x000b7;3 per 1000 person-years in the intervention group and 81&#x000b7;9 per 1000 person-years in the control group. On average, 7&#x000b7;4 persons were treated for a mean of 3&#x000b7;1 years to prevent one case of T2D (equivalent to a number needed to treat (NNT) of 22&#x000b7;9 for one year). In meta-analysis of pooled data from the three EDIPS study cohorts, there was no statistically significant heterogeneity between studies (<xref ref-type="fig" rid="pone-0057143-g002">Figure 2</xref>). Meta-analysis resulted in a pooled risk-ratio of 0&#x000b7;47 (95% CI 0.34&#x02013;0.65).</p><fig id="pone-0057143-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.g001</object-id><label>Figure 1</label><caption><title>CONSORT Flow chart - recruitment by trial cohort and progress of participants.</title><p>The flow chart refers to participants in the EDIPS study with impaired glucose tolerance at baseline.</p></caption><graphic xlink:href="pone.0057143.g001"/></fig><fig id="pone-0057143-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.g002</object-id><label>Figure 2</label><caption><title>Forest plot comparison of the three studies contributing to the EDIPS data-set.</title></caption><graphic xlink:href="pone.0057143.g002"/></fig><table-wrap id="pone-0057143-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics: mean (SD) for continuous variables and number (%) for categorical variables by trial arm.</title></caption><alternatives><graphic id="pone-0057143-t001-1" xlink:href="pone.0057143.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Intervention (n&#x0200a;=&#x0200a;379)</td><td align="left" rowspan="1" colspan="1">Control (n&#x0200a;=&#x0200a;370)</td></tr><tr><td align="left" rowspan="1" colspan="1">Continuous variables</td><td colspan="2" align="left" rowspan="1">Mean value (SD)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">55&#x000b7;4 (8&#x000b7;0)</td><td align="left" rowspan="1" colspan="1">55&#x000b7;7 (8&#x000b7;2)</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kgm<sup>&#x02212;2</sup>)</td><td align="left" rowspan="1" colspan="1">31&#x000b7;4 (5&#x000b7;0)</td><td align="left" rowspan="1" colspan="1">31&#x000b7;0 (4&#x000b7;8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist (cm)</td><td align="left" rowspan="1" colspan="1">102&#x000b7;5 (11&#x000b7;2)</td><td align="left" rowspan="1" colspan="1">101&#x000b7;1 (10&#x000b7;4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hip (cm)</td><td align="left" rowspan="1" colspan="1">109&#x000b7;8 (10&#x000b7;3)</td><td align="left" rowspan="1" colspan="1">108&#x000b7;7 (10&#x000b7;8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">88&#x000b7;2 (14&#x000b7;8)</td><td align="left" rowspan="1" colspan="1">85&#x000b7;7 (13&#x000b7;6)</td></tr><tr><td align="left" rowspan="1" colspan="1">FINDRISC score<sup>11</sup>
</td><td align="left" rowspan="1" colspan="1">14&#x000b7;2 (4&#x000b7;0)</td><td align="left" rowspan="1" colspan="1">14&#x000b7;0 (4&#x000b7;2)</td></tr><tr><td colspan="3" align="left" rowspan="1">Plasma glucose (mmol/l)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Fasting</italic>
</td><td align="left" rowspan="1" colspan="1">6&#x000b7;0 (0&#x000b7;8)</td><td align="left" rowspan="1" colspan="1">6&#x000b7;0 (0&#x000b7;7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;60 minute</italic>
</td><td align="left" rowspan="1" colspan="1">11&#x000b7;2 (2&#x000b7;0)<xref ref-type="table-fn" rid="nt101">a</xref>
</td><td align="left" rowspan="1" colspan="1">11&#x000b7;1 (2&#x000b7;1)<xref ref-type="table-fn" rid="nt102">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;120 minute</italic>
</td><td align="left" rowspan="1" colspan="1">8&#x000b7;8 (1&#x000b7;5)</td><td align="left" rowspan="1" colspan="1">8&#x000b7;7 (1&#x000b7;4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin (mU/l)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Fasting</italic>
</td><td align="left" rowspan="1" colspan="1">13&#x000b7;3 (7&#x000b7;8)<xref ref-type="table-fn" rid="nt103">c</xref>
</td><td align="left" rowspan="1" colspan="1">12&#x000b7;8 (6&#x000b7;6)<xref ref-type="table-fn" rid="nt104">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;120 minute</italic>
</td><td align="left" rowspan="1" colspan="1">84&#x000b7;7 (61&#x000b7;0)<xref ref-type="table-fn" rid="nt105">e</xref>
</td><td align="left" rowspan="1" colspan="1">83&#x000b7;4 (56&#x000b7;7)<xref ref-type="table-fn" rid="nt106">f</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure (systolic) (mmHg)</td><td align="left" rowspan="1" colspan="1">139 (17)</td><td align="left" rowspan="1" colspan="1">137 (16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure (diastolic)(mmHg)</td><td align="left" rowspan="1" colspan="1">84 (9)</td><td align="left" rowspan="1" colspan="1">85 (9)</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (%)</td><td align="left" rowspan="1" colspan="1">5&#x000b7;7 (0&#x000b7;5)<xref ref-type="table-fn" rid="nt107">g</xref>
</td><td align="left" rowspan="1" colspan="1">5&#x000b7;7 (0&#x000b7;5)<xref ref-type="table-fn" rid="nt108">h</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mmoll<sup>&#x02212;1</sup> )</td><td align="left" rowspan="1" colspan="1">5&#x000b7;5 (1&#x000b7;1)<sup>i</sup>
</td><td align="left" rowspan="1" colspan="1">5&#x000b7;5 (1&#x000b7;0)<xref ref-type="table-fn" rid="nt110">j</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmoll<sup>&#x02212;1</sup> )</td><td align="left" rowspan="1" colspan="1">1&#x000b7;7 (0&#x000b7;9)<sup>i</sup>
</td><td align="left" rowspan="1" colspan="1">1&#x000b7;7 (0&#x000b7;8)<xref ref-type="table-fn" rid="nt110">j</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL Cholesterol (mmoll<sup>&#x02212;1</sup> )</td><td align="left" rowspan="1" colspan="1">1&#x000b7;2 (0&#x000b7;3)<sup>i</sup>
</td><td align="left" rowspan="1" colspan="1">1&#x000b7;2 (0&#x000b7;3)<sup>i</sup>
</td></tr></tbody></table><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">
<bold>Categorical variables</bold>
</td><td colspan="2" align="left" rowspan="1">
<bold>Number (%)</bold>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FINDRISC<sup>10</sup> categories</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Low &#x0003c;7</td><td align="left" rowspan="1" colspan="1">6 (1.7)</td><td align="left" rowspan="1" colspan="1">14 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Slightly elevated 7&#x02013;11</td><td align="left" rowspan="1" colspan="1">93 (25.8)</td><td align="left" rowspan="1" colspan="1">85 (23.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate 12&#x02013;14</td><td align="left" rowspan="1" colspan="1">93 (25.8)</td><td align="left" rowspan="1" colspan="1">96 (27.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">High 15&#x02013;20</td><td align="left" rowspan="1" colspan="1">147 (40.7)</td><td align="left" rowspan="1" colspan="1">142 (39.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Very high &#x0003e;20</td><td align="left" rowspan="1" colspan="1">22 (6.1)</td><td align="left" rowspan="1" colspan="1">19 (5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Data unavailable</td><td align="left" rowspan="1" colspan="1">18 (4.7)</td><td align="left" rowspan="1" colspan="1">14 (3.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Male</italic>
</td><td align="left" rowspan="1" colspan="1">145 (38&#x000b7;3)</td><td align="left" rowspan="1" colspan="1">133 (35&#x000b7;9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Female</italic>
</td><td align="left" rowspan="1" colspan="1">234 (61&#x000b7;7)</td><td align="left" rowspan="1" colspan="1">237 (64&#x000b7;1)</td></tr><tr><td colspan="3" align="left" rowspan="1">Socio-economic status by educational level</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Low</italic>
</td><td align="left" rowspan="1" colspan="1">109 (28&#x000b7;8)</td><td align="left" rowspan="1" colspan="1">111 (29&#x000b7;9)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Medium</italic>
</td><td align="left" rowspan="1" colspan="1">97 (25&#x000b7;6)</td><td align="left" rowspan="1" colspan="1">92 (24&#x000b7;8)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;High</italic>
</td><td align="left" rowspan="1" colspan="1">100 (26&#x000b7;4)</td><td align="left" rowspan="1" colspan="1">100 (27&#x000b7;0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Data unavailable</italic>
</td><td align="left" rowspan="1" colspan="1">73 (19&#x000b7;3)</td><td align="left" rowspan="1" colspan="1">67 (18&#x000b7;3)</td></tr><tr><td colspan="3" align="left" rowspan="1">Smoking status</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Non-smoker</italic>
</td><td align="left" rowspan="1" colspan="1">195 (51&#x000b7;5)</td><td align="left" rowspan="1" colspan="1">208 (56&#x000b7;1)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Current smoker</italic>
</td><td align="left" rowspan="1" colspan="1">28 (7&#x000b7;4)</td><td align="left" rowspan="1" colspan="1">38 (10&#x000b7;2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>&#x02003;Data unavailable</italic>
</td><td align="left" rowspan="1" colspan="1">156 (41&#x000b7;2)</td><td align="left" rowspan="1" colspan="1">124 (33&#x000b7;7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label>a</label><p>n&#x0200a;=&#x0200a;348.</p></fn><fn id="nt102"><label>b</label><p>n&#x0200a;=&#x0200a;330.</p></fn><fn id="nt103"><label>c</label><p>n&#x0200a;=&#x0200a;354.</p></fn><fn id="nt104"><label>d</label><p>n&#x0200a;=&#x0200a;348.</p></fn><fn id="nt105"><label>e</label><p>n&#x0200a;=&#x0200a;351.</p></fn><fn id="nt106"><label>f</label><p>n&#x0200a;=&#x0200a;344.</p></fn><fn id="nt107"><label>g</label><p>n&#x0200a;=&#x0200a;370.</p></fn><fn id="nt108"><label>h</label><p>n&#x0200a;=&#x0200a;362.</p></fn><fn id="nt109"><label>I</label><p>n&#x0200a;=&#x0200a;375.</p></fn><fn id="nt110"><label>j</label><p>n&#x0200a;=&#x0200a;364.</p></fn></table-wrap-foot></table-wrap><p>Cox-regression analysis, controlling for trial cohort, suggested the cumulative incidence of T2D was 57% lower in the intervention than in the control group (hazard ratio 0&#x000b7;43 (95% CI 0&#x000b7;30 to 0&#x000b7;61); P&#x0003c;0&#x000b7;001) (<xref ref-type="fig" rid="pone-0057143-g003">Figure 3</xref>) (this differs from the risk ratio above (<xref ref-type="fig" rid="pone-0057143-g002">Figure 2</xref>), which does not account for survival). In sex-specific analyses, cumulative incidence of T2D was 63% lower for males (hazard ratio 0&#x000b7;37 (95% CI 0&#x000b7;21 to 0&#x000b7;65); P&#x0003c;0.001) and 52% lower for females (hazard ratio 0&#x000b7;48 (95% CI 0&#x000b7;30 to 0&#x000b7;77); P&#x0003c;0.001).</p><fig id="pone-0057143-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.g003</object-id><label>Figure 3</label><caption><title>Progression to type 2 diabetes by trial arm.</title></caption><graphic xlink:href="pone.0057143.g003"/></fig><p>Cox-regression analysis of a sub-set (n&#x0200a;=&#x0200a;632) in which cases having a single baseline value of FPG&#x02265;7&#x000b7;0 mmoll<sup>&#x02212;1</sup> or HbA<sub>1c</sub> &#x02265;6&#x000b7;5% were removed, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref> showed 62% reduction in T2D risk in the intervention group compared with the control group (hazard ratio 0&#x000b7;38 (95% CI 0&#x000b7;25 to 0&#x000b7;60), P&#x0003c;0&#x000b7;001).</p></sec><sec id="s3b"><title>Impact of Weight Loss Maintenance</title><p>In the intervention group, 144 (38%) achieved &#x02265;5% weight loss at Year 1, 105 (28%) maintained this at Year 2 and 86 (23%) at Year 3; whilst in the control group 50 (14%) achieved &#x02265;5% weight loss at year one, 26 (7%) maintained this at year two, and 18 (5%) at year three (Chi-Squared tests, p&#x0003c;0&#x000b7;0001 for difference in the proportions achieving weight loss between intervention and control groups at each time point). Cox-regression analysis of pooled (intervention and control group) data, showed that participants who achieved &#x02265;5% weight loss at year one had 64% lower T2D incidence (hazard ratio 0&#x000b7;36 (95% CI 0&#x000b7;22 to 0&#x000b7;56); P&#x0003c;0&#x000b7;001), those who maintained this at year two had 79% lower T2D risk (hazard ratio 0&#x000b7;21 (95% CI 0&#x000b7;09 to 0&#x000b7;49) P&#x0003c;0&#x000b7;001), and those who maintained this at year three had 89% lower T2D risk (hazard ratio 0&#x000b7;11 (95% CI 0&#x000b7;04 to 0&#x000b7;35) P&#x0003c;0&#x000b7;001) (<xref ref-type="fig" rid="pone-0057143-g004">Figure 4</xref>). There were no statistically significant differences in any of the baseline variables (as listed in <xref ref-type="table" rid="pone-0057143-t001">Table 1</xref>) for those who met, or did not meet, these weight loss goals, other than a slightly lower baseline age for those achieving the weight loss goal in the first year (54&#x000b7;4 years compared with 56&#x000b7;0 years; P&#x0200a;=&#x0200a;0&#x000b7;02). Analysis of effects of weight loss using only intervention group data produced similar results.</p><fig id="pone-0057143-g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.g004</object-id><label>Figure 4</label><caption><title>Progression to type 2 diabetes by weight loss achieved and maintained.</title></caption><graphic xlink:href="pone.0057143.g004"/></fig><p>Cases achieving &#x02265;5% weight loss at Year 1 numbered 194 (I&#x0200a;=&#x0200a;144, C&#x0200a;=&#x0200a;50). Results of Cox- regression survival analysis of T2DM incidence in the intervention compared with the control group showed HR 0.41(95% CI 0.16 to 1.03) p&#x0200a;=&#x0200a;0.06 (B (SE) &#x02212;0.90 (0.47)).</p></sec><sec id="s3c"><title>Consideration of Risk Score and Hyperglycaemia Cut-point Values for Risk Identification</title><p>The number of EDIPS participants (all of whom had IGT) who would have been identified at baseline by FPG or HbA<sub>1c</sub> cut points, as recommended by NICE, ADA and WHO, <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref>, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref>, <xref rid="pone.0057143-AmericanDiabetes2" ref-type="bibr">[25]</xref> are shown in <xref ref-type="table" rid="pone-0057143-t002">Table 2</xref>, with Cox-regression hazard ratios for progression to T2D. Applying the proposed NICE guidance FPG and HbA<sub>1c</sub> cut-points to the EDIPS cohort of adults with IGT would have identified 66.8% (hazard ratio for progression to T2D 0&#x000b7;48 (95% CI 0&#x000b7;30 to 0&#x000b7;75) P&#x0003c;0.001) using FPG cut-points, but only 17.9% (hazard ratio 0&#x000b7;34 (95% CI 0&#x000b7;16 to 0&#x000b7;72) using HbA<sub>1c</sub> cut-points, whereas applying the ADA cut points for HbA<sub>1c</sub> would have identified 42.2% (hazard ratio 0.38 (95% CI 0.19 to 0.76) of EDIPS participants.</p><table-wrap id="pone-0057143-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.t002</object-id><label>Table 2</label><caption><title>EDIPS cases identified by high-risk FINDRISC<sup>10</sup> score or by cut-points for fasting plasma glucose (FPG) and glycated Haemoglobin (HbA1c) as specified by NICE, ADA and WHO with risk statistics for intervention and control groups compared.</title></caption><alternatives><graphic id="pone-0057143-t002-2" xlink:href="pone.0057143.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Moderate or lower risk</td><td colspan="2" align="left" rowspan="1">High or greater risk</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>FNDRISC <sup>a 10</sup></bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;15</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;15</bold>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>387 (51&#x000b7;7))</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>330 (44&#x000b7;1)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE) for</italic>
<italic>intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;62 (0&#x000b7;37 to 1&#x000b7;05)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;072 &#x02212;0.5(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;30 (0&#x000b7;20 to 0&#x000b7;51)</italic>
<italic>P&#x0003c;0&#x000b7;001 &#x02212;1.2(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>FPG (mmoll</bold>
<sup>&#x02212;<bold>1</bold></sup>
<bold> )</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Lower risk</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>High risk</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Diabetic range</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NICE ranges</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;5&#x000b7;5</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5&#x000b7;5 to 6&#x000b7;9 (99 to 125</bold>
<bold>mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;7&#x000b7;0</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>178 (23&#x000b7;8)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>500 (66&#x000b7;8)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>71 (9&#x000b7;5)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE) for</italic>
<italic>intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;29 (0&#x000b7;12 to 0&#x000b7;71)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;007 &#x02212;1.2(0.5)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;48 (0&#x000b7;30 to 0&#x000b7;75)</italic>
<italic>P&#x0003c;0&#x000b7;001 &#x02212;0.7(0.2)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ADA ranges</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;5&#x000b7;6</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5&#x000b7;6 to 6&#x000b7;9 (100 to 125 mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;7&#x000b7;0</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>214 (28&#x000b7;6)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>464 (61&#x000b7;9)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>71 (9&#x000b7;5)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE)</italic>
<italic>for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;26 (0&#x000b7;11 to 0&#x000b7;61)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;002 &#x02212;1.4(0.4)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;51(0&#x000b7;32 to 0&#x000b7;82)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;005 &#x02212;0.7(0.2)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">WHO ranges</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;6&#x000b7;1</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6&#x000b7;1 to 6&#x000b7;9 (110 to 125 mg/dl)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;7&#x000b7;0</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>404 (53&#x000b7;9)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>268 (35&#x000b7;8)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>71 (9&#x000b7;5)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE)</italic>
<italic>for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;43 (0&#x000b7;24 to 0&#x000b7;77)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;005 &#x02212;0.8(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;40 (0&#x000b7;22 to 0&#x000b7;71)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;002 &#x02212;1.0(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HbA1c<sup>b</sup> (%)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Lower risk</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>High risk</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>Diabetic range</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NICE and UK-NSC ranges</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;6&#x000b7;0</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>6&#x000b7;0 to 6&#x000b7;4 (42&#x02013;47 mmol/mol)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;6&#x000b7;5</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>539 (72&#x000b7;0)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>134 (17&#x000b7;9)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>59 (7&#x000b7;9)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE)</italic>
<italic>for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;44 (0&#x000b7;27 to 0&#x000b7;68)</italic>
<italic>P&#x0003c;0&#x000b7;001 &#x02212;0.8(0.2)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;34 (0&#x000b7;16 to 0&#x000b7;72)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;005 &#x02212;1.1(0.4)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ADA ranges</td><td align="left" rowspan="1" colspan="1">
<bold>&#x0003c;5&#x000b7;7</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>5&#x000b7;7 to 6&#x000b7;4 (39&#x02013;47 mmol/mol)</bold>
</td><td align="left" rowspan="1" colspan="1">
<bold>&#x02265;6&#x000b7;5</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>357 (47&#x000b7;7)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>316 (42&#x000b7;2)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>59 (7&#x000b7;9)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE)</italic>
<italic>for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;42 (0&#x000b7;26 to 0&#x000b7;70)</italic>
<italic>P&#x0003c;0&#x000b7;001&#x02013;0.8(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;38 (0&#x000b7;19 to 0&#x000b7;76)</italic>
<italic>P&#x0200a;=&#x0200a;0&#x000b7;006 &#x02212;1.0(0.4)</italic>
</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives></table-wrap><p>The number of EDIPS cases that would have been identified at baseline by FINDRISC scores only, and combined with high-risk FPG and HbA1c cut-points (mimicking the NICE guidance proposed two stage screening process <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> ) are shown in <xref ref-type="table" rid="pone-0057143-t003">Table 3</xref>. Applying the FINDRISC cut point for moderate risk (&#x02265;12) to the EDIPS IGT cohort would have identified 69&#x000b7;3% (hazard ratio 0&#x000b7;42 (95% CI 0&#x000b7;20 to 0&#x000b7;51) P&#x0003c;0&#x000b7;001) of participants. A combination of FINDRISC &#x02265;12 and FPG 5&#x000b7;5 to 6&#x000b7;9 mmoll<sup>&#x02212;1</sup> would have identified 49&#x000b7;4% (hazard ratio 0&#x000b7;48 (0&#x000b7;28 to 0&#x000b7;83) P&#x0003c;0&#x000b7;001) whereas a combination of FINDRISC &#x02265;12 and HbA1c 6&#x000b7;0 to 6&#x000b7;4% would have identified only 13&#x000b7;7% (hazard ratio 0&#x000b7;46 (95% CI 0&#x000b7;24 to 0&#x000b7;76) P&#x0200a;=&#x0200a;0&#x000b7;08) of EDIPS participants <xref rid="pone.0057143-AmericanDiabetes1" ref-type="bibr">[24]</xref>.</p><table-wrap id="pone-0057143-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057143.t003</object-id><label>Table 3</label><caption><title>EDIPS cases identified by FINDRISC<sup>10</sup> and high risk cut-points for fasting plasma glucose (FPG) and glycated Haemoglobin (HbA1c) as specified by NICE, ADA and WHO with risk statistics for intervention and control groups compared.</title></caption><alternatives><graphic id="pone-0057143-t003-3" xlink:href="pone.0057143.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td colspan="2" align="left" rowspan="1">FINDRISC score cut-points</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Moderate or greater risk (&#x02265;12)</td><td align="left" rowspan="1" colspan="1">High or greater risk (&#x02265;15)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>FINDRISC</bold>
<xref ref-type="table-fn" rid="nt111">a</xref>
<bold>score only</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>519 (69&#x000b7;3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>330 (44&#x000b7;1)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;43 (0&#x000b7;28 to 0.66)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;30 (0&#x000b7;20 to 0&#x000b7;51)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0003c;0&#x000b7;001&#x02013;0.8(0.2)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0003c;0&#x000b7;001 &#x02212;1.2(0.3)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>FPG (mmoll</bold>
<sup>&#x02212;<bold>1</bold></sup>
<bold> )</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NICE high risk range (5&#x000b7;5 to 6&#x000b7;9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>354 (49&#x000b7;4)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>224 (31&#x000b7;2)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;48 (0&#x000b7;28 to 0&#x000b7;83)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;39 (0&#x000b7;20 to 0&#x000b7;78)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;008 &#x02212;0.9(0.4)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;008 &#x02212;0.9(0.4)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ADA high risk range (5&#x000b7;6 to 6&#x000b7;9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>328 (45&#x000b7;7)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>209 (29&#x000b7;1)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;51 (0.30 to 0.87)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;41 (0&#x000b7;21 to 0&#x000b7;83)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;014 &#x02212;0.7(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;007 &#x02212;0.9(0.4)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">WHO high risk range (6&#x000b7;1 to 6&#x000b7;9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>198 (27&#x000b7;6)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>62 (8&#x000b7;9)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI), P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;37 (0.23 to 0.64)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;31 (0&#x000b7;13 to 0&#x000b7;73)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;003 &#x02212;1.0(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;007 &#x02212;0.9(0.4)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>HbA1c</bold>
<xref ref-type="table-fn" rid="nt112">b</xref>
<bold>(%)</bold>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">NICE and UK-NSC high risk range (6&#x000b7;0 to 6&#x000b7;4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>96 (13&#x000b7;7)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>62 (8&#x000b7;9)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI) P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;46 (0&#x000b7;19 to 1&#x000b7;10)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;35 (0&#x000b7;12 to 1&#x000b7;00)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;08 &#x02212;0.8(0.4)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;05 &#x02212;1.1(0.5)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ADA high risk range</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>EDIPS cases n (%)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>227 (32&#x000b7;4)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>158 (22&#x000b7;6)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Hazard ratio (95% CI),P value and B(SE) for intervention/control incidence</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;43 (0&#x000b7;24 to 0&#x000b7;76)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>0&#x000b7;28 (0&#x000b7;13 to 0&#x000b7;59)</italic>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;004 &#x02212;0.8(0.3)</italic>
</td><td align="left" rowspan="1" colspan="1">
<italic>P&#x0200a;=&#x0200a;0&#x000b7;001 (&#x02212;1.2(0.4)</italic>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt111"><label>a</label><p>n&#x0200a;=&#x0200a;717.</p></fn><fn id="nt112"><label>b</label><p>n&#x0200a;=&#x0200a;732.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><sec id="s4a"><title>Principal Findings</title><p>The analysis presented here reinforces existing evidence for the effectiveness of intensive lifestyle interventions to prevent T2D in adults with IGT and provides evidence for the generalisability of such interventions to European populations. Incidence of T2D was reduced by 57% in the intervention group compared with the control group. Explanatory analysis supported a &#x02265;5% weight loss goal, as advocated in the EDIPS protocol and by NICE, <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> in this population and highlighted the importance of sustained weight loss long term (&#x0003e;1 year). Recently proposed cut-points, using a risk score (such as FINDRISC) and a blood test (FPG or HbA<sub>1c</sub>), to identify individuals at high-risk would have identified substantially different proportions of the EDIPS cohort of adults with IGT with little variation in the hazard ratios for T2D incidence. This analysis demonstrates the difficulties in efficiently identifying a population for targeting interventions, where progressive risk and evidence of potential to benefit, and intervention cost and capacity to deliver, are appropriately balanced.</p></sec><sec id="s4b"><title>Strengths and Limitations of the Study</title><p>The EDIPS RCTs were conducted in three culturally different populations, recruited over a 10 year period, and the consistency of findings in different countries confirms the generalisability of the lifestyle intervention originally designed for the DPS. We might have expected the results of earlier diabetes prevention trials to influence control group participants in the later EDIPS cohorts, thus diluting the intervention effect, but there was little evidence that this occurred.</p><p>EDIPS was conducted in a population of white European ethnicity. In people of South Asian or African origin ethnicity, T2D risk is elevated. Trials elsewhere have demonstrated efficacy of lifestyle-based interventions for T2D prevention in these populations, <xref rid="pone.0057143-Ramachandran1" ref-type="bibr">[26]</xref> but not so far in Europe, although trials among South Asians living in Scotland, <xref rid="pone.0057143-Douglas1" ref-type="bibr">[27]</xref> London (G A Hitman personal communication), Leicester (K Khunti personal communication) and Oslo <xref rid="pone.0057143-Hjellset1" ref-type="bibr">[28]</xref> are underway.</p><p>The EDIPS protocol was common to all three cohorts. The approach recognised the necessity for some local variation in intervention delivery to achieve cultural resonance, but the intervention goals, intensity and mode of delivery were similar. Changes to the diagnostic criteria for T2D since the design of EDIPS would have excluded some participants because they would have been diagnosed with T2D during recruitment. <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref>, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref> However, analysis of a sub-set of cases with FPG&#x02265;7&#x000b7;0 mmoll<sup>&#x02212;1</sup> and HbA1C&#x02265;6&#x000b7;5% removed did not alter the observed intervention effect. Diagnosis of T2D at annual follow-up was based on two hour venous plasma glucose values in an OGTT, <xref rid="pone.0057143-World1" ref-type="bibr">[18]</xref> thus some people were retained in the study with FPG&#x02265;7&#x000b7;0 mmoll<sup>&#x02212;1</sup> or HbA1C&#x02265;6&#x000b7;5% who may have been diagnosed with T2D under later criteria <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref>, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref>.</p></sec><sec id="s4c"><title>Comparisons with Other Studies</title><p>The 57% overall reduction in T2D incidence, with a NNT of 7&#x000b7;4, observed in EDIPS is in line with outcomes of other diabetes prevention RCTs; meta-analysis of diet and/or exercise intervention studies has shown a pooled hazard ratio of 0&#x000b7;51 (95% CI 0&#x000b7;44 to 0&#x000b7;60) and NNT of 6&#x000b7;4. <xref rid="pone.0057143-Gillies1" ref-type="bibr">[6]</xref> The recently published DE-PLAN-CAT-PREDICE study <xref rid="pone.0057143-Costa1" ref-type="bibr">[29]</xref> screened participants using FINDRISC (&#x02265;14) with subsequent OGTT to identify IFG or IGT (WHO classifications). <xref rid="pone.0057143-World2" ref-type="bibr">[22]</xref>, <xref rid="pone.0057143-World3" ref-type="bibr">[23]</xref>, <xref rid="pone.0057143-Costa1" ref-type="bibr">[29]</xref> Comparison of the lifestyle intervention and standard care control groups showed risk reduction of 36&#x000b7;5%. This lower effectiveness may reflect the different study population (both different ethnicity and inclusion of IFG identified high risk participants) or different intervention, or both.</p><p>Recently data were published from a trial <xref rid="pone.0057143-Saito1" ref-type="bibr">[30]</xref> where the primary inclusion criterion was IFG (ADA range: FPG 5&#x000b7;6 to 6&#x000b7;9 mmoll<sup>&#x02212;1</sup>). <xref rid="pone.0057143-AmericanDiabetes1" ref-type="bibr">[24]</xref> Overall, lifestyle intervention reduced T2D risk by 44%. However, post-hoc sub-group analyses showed a positive intervention effect in the IFG+IGT group (HR 0&#x000b7;41 (95% CI 0&#x000b7;24 to 0.69), and IFG+HbA<sub>1c</sub> (HbA1c&#x02265;5.6%) group (HR 0&#x000b7;24 (95% CI 0&#x000b7;12 to 0&#x000b7;48) only. In people with isolated IFG, who comprised almost 60% of participants, no effect was observed (17% non-significant increase in risk).</p><p>Weight loss is attractive for monitoring compliance with interventions in routinely provided services, because it can be easily and objectively measured. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> By pooling data from intervention and control groups for the analysis of weight loss and T2D incidence, we sought to evaluate the utility of sustained weight loss as an intermediate health outcome. Our explanatory analysis of the EDIPS data set of adults of white European ethnicity with IGT showed that achieving &#x02265;5% weight loss at one year reduced T2D incidence by 64%, with enhanced effect if sustained at two or three years. Analysis of T2D incidence in those achieving &#x02265;5% weight loss at Year 1 suggests that additional features of the intervention, such as increased physical activity and improved nutrition, contributed to the reduction in T2D incidence in these intervention group participants who also lost more weight on average and retained their weight loss for longer.</p><p>Translational studies to date, with the exception of the GOAL <xref rid="pone.0057143-Absetz1" ref-type="bibr">[31]</xref> and the DE-PLAN-CAT-PREDICE studies, <xref rid="pone.0057143-Costa1" ref-type="bibr">[29]</xref> have had follow-up of one year or less and have focussed on weight loss as an intermediate health outcome. In a behaviour change RCT it is impossible to exclude self-help within the control group, especially where giving basic advice is ethically appropriate and regular monitoring is required for those at risk. In our qualitative evaluation, nested within the EDIPS-Newcastle trial, many participants reported that it took two years to establish lifestyle changes, suggesting that prolonged intervention may be required to maximise weight loss maintenance and thus effective prevention of T2D in those at high-risk <xref rid="pone.0057143-Penn2" ref-type="bibr">[32]</xref>.</p><p>The mean duration of the EDIPS trials was 3.1 years. Sustained reduction in the incidence of T2D and the mediating effect of weight loss have been shown in follow-up studies of the DPS <xref rid="pone.0057143-Lindstrm1" ref-type="bibr">[14]</xref> and the US Diabetes Prevention Programme. <xref rid="pone.0057143-Diabetes1" ref-type="bibr">[13]</xref> However, in the Indian diabetes prevention study <xref rid="pone.0057143-Ramachandran2" ref-type="bibr">[33]</xref> a small weight loss in the lifestyle intervention group at six months was not sustained and the efficacy of weight loss for T2D prevention in people of South Asian ethnicity remains unclear. Whilst reducing progression to T2D in individuals at high-risk is important, there is also a need for population level interventions to reverse the rise in obesity in order to reduce T2D incidence <xref rid="pone.0057143-NICE2" ref-type="bibr">[3]</xref>.</p></sec><sec id="s4d"><title>Possible Mechanisms and Implications for Clinicians and Policymakers</title><p>Translating evidence on the effectiveness of lifestyle intervention for prevention of T2D in adults with IGT into cost-effective, scalable interventions is challenging, especially in an era of budgetary constraints.</p><p>Among these challenges is the efficient identification of individuals at high-risk for effective, targeted intervention. Translational studies focus on risk identification using prospective risk scores. <xref rid="pone.0057143-Douglas2" ref-type="bibr">[34]</xref> For example, recent studies in Spain and Finland have demonstrated the effect of lifestyle intervention where recruitment was based on FINDRISC. <xref rid="pone.0057143-Costa1" ref-type="bibr">[29]</xref>, <xref rid="pone.0057143-Saaristo2" ref-type="bibr">[35]</xref> The screening strategy proposed in the NICE guidance advocates a risk score (such as FINDRISC), followed by a single blood test (either FPG or HbA1c) to identify individuals at high T2D risk. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> Applying the cut-points proposed by NICE to the EDIPS cohort shows that determining pragmatic, acceptable, low cost risk assessment with high predictive value in identifying individuals with the greatest potential to benefit from a T2D prevention intervention remains a challenge. The optimum combination of risk-score and blood test values for use in routine practice remains unclear and further research is needed, including economic evaluation.</p><p>Our explanatory analysis suggests that sustained weight loss at two and three years enhanced the intervention effect in the EDIPS cohort. The most efficient duration and intensity of lifestyle interventions to maintain weight loss <xref rid="pone.0057143-Dombrowski1" ref-type="bibr">[36]</xref> or to prevent T2D in individuals at high-risk remain uncertain. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> The economic modelling undertaken for the NICE guidance development suggests that screening and intervention for T2D prevention is highly likely to be cost-effective, at a threshold of &#x000a3;10,000 per quality adjusted life year (QALY) gained or less, but the authors acknowledge that the results are based on assumptions about prevention effectiveness in individuals at high-risk identified by criteria other than IGT. <xref rid="pone.0057143-NICE1" ref-type="bibr">[2]</xref> Our analyses provide an indication of intervention effectiveness, identified by a range of risk criteria.</p></sec><sec id="s4e"><title>Unanswered Questions and Future Research</title><p>The screening strategy proposed in the NICE guidance is pragmatic, but our results show that the proposed cut-points for HbA<sub>1c</sub> or FPG would identify different high-risk groups from those with IGT. Research is needed to demonstrate the effectiveness of lifestyle interventions on T2D incidence in populations identified by different combinations and ranges of risk scores, FPG and HbA<sub>1c</sub> values to identify the optimum risk assessment strategy in terms of both patient benefit and cost-effectiveness. The incidence and prevalence of T2D are socio-economically patterned and there is therefore a need to develop lifestyle interventions for T2D prevention that are accessible, culturally adapted and which reduce social inequalities in outcomes. <xref rid="pone.0057143-White1" ref-type="bibr">[37]</xref> However, the evidence to date, including the present study, suggests that lifestyle interventions are effective in diverse human populations.</p><p>Robust evaluations of pragmatic interventions for T2D prevention are needed that can be delivered efficiently in the context of routine health care provision and with sufficient duration for T2D incidence to be the primary outcome.</p></sec><sec id="s4f"><title>Conclusion</title><p>The European Diabetes Prevention Study reinforces evidence that intensive lifestyle intervention can prevent T2D in adults with IGT, and provides evidence of wider generalisability in European populations. Analyses demonstrated the preventive effect of &#x02265;5% weight loss, especially if maintained long term, which suggests the utility of a &#x02265;5% weight loss target for intervention monitoring.</p><p>Proposed blood test cut-points for high&#x02013;risk would have identified different proportions of the EDIPS cohort, with similar intervention benefit. Identification of high-risk individuals for provision of T2D prevention should consider risk profile along with potential to benefit, as well as overall cost-effectiveness and equity of outcomes.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0057143.s001"><label>Checklist S1</label><caption><p>
<bold>CONSORT checklist.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0057143.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0057143.s002"><label>Protocol S1</label><caption><p>
<bold>European Diabetes Prevention Study Protocol.</bold>
</p><p>(DOC)</p></caption><media xlink:href="pone.0057143.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank all the EDIPS participants and the staff who were involved with the studies. Full acknowledgements appear in the papers reporting each EDIPS cohort. <xref rid="pone.0057143-Tuomilehto1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057143-Roumen1" ref-type="bibr">[7]</xref>, <xref rid="pone.0057143-Penn1" ref-type="bibr">[8]</xref>
</p></ack><ref-list><title>References</title><ref id="pone.0057143-InternationalDiabetes1"><label>1</label><mixed-citation publication-type="other">International Diabetes Federation (2011) Diabetes Atlas 5th edition. Brussels.</mixed-citation></ref><ref id="pone.0057143-NICE1"><label>2</label><mixed-citation publication-type="other">NICE (2012) PH 38 Preventing type 2 diabetes - risk identification and interventions for individuals at high risk. Available: <ext-link ext-link-type="uri" xlink:href="http://guidanceniceorguk/PH38">http://guidanceniceorguk/PH38</ext-link>. London.</mixed-citation></ref><ref id="pone.0057143-NICE2"><label>3</label><mixed-citation publication-type="other">NICE (2011) PH35 Preventing type 2 diabetes - population and community interventions: supporting evidence. Available: <ext-link ext-link-type="uri" xlink:href="http://guidanceniceorguk/PH35">http://guidanceniceorguk/PH35</ext-link>. London.</mixed-citation></ref><ref id="pone.0057143-Chatterton1"><label>4</label><mixed-citation publication-type="other">Chatterton H, Younger T, Fischer A, Khunti K (2012) Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 345.</mixed-citation></ref><ref id="pone.0057143-Tuomilehto1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Tuomilehto</surname><given-names>J</given-names></name>, <name><surname>Lindstrom</surname><given-names>J</given-names></name>, <name><surname>Eriksson</surname><given-names>JG</given-names></name>, <name><surname>Valle</surname><given-names>TT</given-names></name>, <name><surname>Hamalainen</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance</article-title>. <source>New England Journal of Medicine</source>
<volume>344</volume>: <fpage>1343</fpage>&#x02013;<lpage>1350</lpage>.<pub-id pub-id-type="pmid">11333990</pub-id></mixed-citation></ref><ref id="pone.0057143-Gillies1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Gillies</surname><given-names>CL</given-names></name>, <name><surname>Abrams</surname><given-names>KR</given-names></name>, <name><surname>Lambert</surname><given-names>PC</given-names></name>, <name><surname>Cooper</surname><given-names>NJ</given-names></name>, <name><surname>Sutton</surname><given-names>AJ</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis</article-title>. <source>BMJ</source>
<volume>334</volume>: <fpage>299</fpage>.<pub-id pub-id-type="pmid">17237299</pub-id></mixed-citation></ref><ref id="pone.0057143-Roumen1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Roumen</surname><given-names>C</given-names></name>, <name><surname>Corpeleijn</surname><given-names>E</given-names></name>, <name><surname>Feskens</surname><given-names>EJM</given-names></name>, <name><surname>Mensink</surname><given-names>M</given-names></name>, <name><surname>Saris</surname><given-names>WHM</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study</article-title>. <source>Diabetic Medicine</source>
<volume>25</volume>: <fpage>597</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">18445174</pub-id></mixed-citation></ref><ref id="pone.0057143-Penn1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Penn</surname><given-names>L</given-names></name>, <name><surname>White</surname><given-names>M</given-names></name>, <name><surname>Oldroyd</surname><given-names>J</given-names></name>, <name><surname>Walker</surname><given-names>M</given-names></name>, <name><surname>Alberti</surname><given-names>KGMM</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK</article-title>. <source>BMC Public Health</source>
<volume>9</volume>: <fpage>342</fpage>.<pub-id pub-id-type="pmid">19758428</pub-id></mixed-citation></ref><ref id="pone.0057143-Uusitupa1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Uusitupa</surname><given-names>M</given-names></name>, <name><surname>Tuomilehto</surname><given-names>J</given-names></name>, <name><surname>Puska</surname><given-names>P</given-names></name> (<year>2011</year>) <article-title>Are we really active in the prevention of obesity and type 2 diabetes at the community level?</article-title>
<source>Nutrition, metabolism, and cardiovascular diseases: NMCD</source>
<volume>21</volume>: <fpage>380</fpage>&#x02013;<lpage>389</lpage>.</mixed-citation></ref><ref id="pone.0057143-TheFinnishDiabetes1"><label>10</label><mixed-citation publication-type="other">The Finnish Diabetes Association (2003) DEHKO &#x02013; Development Programme for the Prevention and Care of Diabetes in Finland 2000&#x02013;2010.</mixed-citation></ref><ref id="pone.0057143-Saaristo1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Saaristo</surname><given-names>T</given-names></name>, <name><surname>Peltonen</surname><given-names>M</given-names></name>, <name><surname>Kein&#x000e4;nen-Kiukaanniemi</surname><given-names>S</given-names></name>, <name><surname>Vanhala</surname><given-names>M</given-names></name>, <name><surname>Saltevo</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>National type 2 diabetes prevention programme in Finland: FIN-D2D</article-title>. <source>Int J Circumpolar Health</source>
<volume>66</volume>: <fpage>101</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="pmid">17515250</pub-id></mixed-citation></ref><ref id="pone.0057143-Lindstrom1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Lindstrom</surname><given-names>J</given-names></name>, <name><surname>Tuomilehto</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>The diabetes risk score: a practical tool to predict type 2 diabetes risk</article-title>. <source>Diabetes Care</source>
<volume>26</volume>: <fpage>725</fpage>&#x02013;<lpage>731</lpage>.<pub-id pub-id-type="pmid">12610029</pub-id></mixed-citation></ref><ref id="pone.0057143-Diabetes1"><label>13</label><mixed-citation publication-type="journal">
<collab>Diabetes Prevention Program Research G</collab> (<year>2009</year>) <article-title>10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study</article-title>. <source>The Lancet</source>
<volume>374</volume>: <fpage>1677</fpage>&#x02013;<lpage>1686</lpage>.</mixed-citation></ref><ref id="pone.0057143-Lindstrm1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Ilanne-Parikka</surname><given-names>P</given-names></name>, <name><surname>Peltonen</surname><given-names>M</given-names></name>, <name><surname>Aunola</surname><given-names>S</given-names></name>, <name><surname>Eriksson</surname><given-names>JG</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study</article-title>. <source>The Lancet</source>
<volume>368</volume>: <fpage>1673</fpage>&#x02013;<lpage>1679</lpage>.</mixed-citation></ref><ref id="pone.0057143-Hamman1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Hamman</surname><given-names>RF</given-names></name>, <name><surname>Wing</surname><given-names>RR</given-names></name>, <name><surname>Edelstein</surname><given-names>SL</given-names></name>, <name><surname>Lachin</surname><given-names>JM</given-names></name>, <name><surname>Bray</surname><given-names>GA</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Effect of weight loss with lifestyle intervention on risk of diabetes</article-title>. <source>Diabetes Care</source>
<volume>29</volume>: <fpage>2102</fpage>&#x02013;<lpage>2107</lpage>.<pub-id pub-id-type="pmid">16936160</pub-id></mixed-citation></ref><ref id="pone.0057143-Lindstrm2"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Louheranta</surname><given-names>A</given-names></name>, <name><surname>Mannelin</surname><given-names>M</given-names></name>, <name><surname>Rastas</surname><given-names>M</given-names></name>, <name><surname>Salminen</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>The Finnish Diabetes Prevention Study (DPS). Lifestyle, intervention and 3-year results on diet and physical activity</article-title>. <source>Diabetes Care</source>
<volume>2003</volume>: <fpage>3230</fpage>&#x02013;<lpage>3236</lpage>.</mixed-citation></ref><ref id="pone.0057143-Roumen2"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Roumen</surname><given-names>C</given-names></name>, <name><surname>Feskens</surname><given-names>EJM</given-names></name>, <name><surname>Corpeleijn</surname><given-names>E</given-names></name>, <name><surname>Mensink</surname><given-names>M</given-names></name>, <name><surname>Saris</surname><given-names>WHM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Predictors of lifestyle intervention outcome and dropout: the SLIM study</article-title>. <source>Eur J Clin Nutr</source>
<volume>65</volume>: <fpage>1141</fpage>&#x02013;<lpage>1147</lpage>.<pub-id pub-id-type="pmid">21587283</pub-id></mixed-citation></ref><ref id="pone.0057143-World1"><label>18</label><mixed-citation publication-type="other">World Health Organization (1985) Diabetes Mellitus: report of a WHO Study Group. Technical Report Series No 727. Geneva.</mixed-citation></ref><ref id="pone.0057143-NetherlandsNutrition1"><label>19</label><mixed-citation publication-type="other">Netherlands Nutrition Council (1986) Guidelines for a healthy diet. The Hague.</mixed-citation></ref><ref id="pone.0057143-Rollnick1"><label>20</label><mixed-citation publication-type="other">Rollnick S, Mason P, Butler C (1999) Health Behaviour Change. Edinburgh: Churchill livingstone.</mixed-citation></ref><ref id="pone.0057143-Eriksson1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Eriksson</surname><given-names>KF</given-names></name>, <name><surname>Lindgarde</surname><given-names>F</given-names></name> (<year>1991</year>) <article-title>Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study</article-title>. <source>Diabetologia</source>
<volume>34</volume>: <fpage>891</fpage>&#x02013;<lpage>898</lpage>.<pub-id pub-id-type="pmid">1778354</pub-id></mixed-citation></ref><ref id="pone.0057143-World2"><label>22</label><mixed-citation publication-type="other">World Health Organisation (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus Report of a WHO Consultation. Geneva.</mixed-citation></ref><ref id="pone.0057143-World3"><label>23</label><mixed-citation publication-type="other">World Health Organisation (2011) Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation. Geneva.</mixed-citation></ref><ref id="pone.0057143-AmericanDiabetes1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>American Diabetes</surname><given-names>A</given-names></name> (<year>2010</year>) <article-title>Diagnosis and Classification of Diabetes Mellitus</article-title>. <source>Diabetes Care</source>
<volume>33</volume>: <fpage>S62</fpage>&#x02013;<lpage>S69</lpage>.<pub-id pub-id-type="pmid">20042775</pub-id></mixed-citation></ref><ref id="pone.0057143-AmericanDiabetes2"><label>25</label><mixed-citation publication-type="other">American Diabetes Association (2010) Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 33.</mixed-citation></ref><ref id="pone.0057143-Ramachandran1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Ramachandran</surname><given-names>A</given-names></name>, <name><surname>Snehalatha</surname><given-names>C</given-names></name>, <name><surname>Mary</surname><given-names>S</given-names></name>, <name><surname>Mukesh</surname><given-names>B</given-names></name>, <name><surname>Bhaskar</surname><given-names>AD</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)</article-title>. <source>Diabetologia</source>
<volume>49</volume>: <fpage>289</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">16391903</pub-id></mixed-citation></ref><ref id="pone.0057143-Douglas1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Douglas</surname><given-names>A</given-names></name>, <name><surname>Bhopal</surname><given-names>R</given-names></name>, <name><surname>Bhopal</surname><given-names>R</given-names></name>, <name><surname>Forbes</surname><given-names>J</given-names></name>, <name><surname>Gill</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Recruiting South Asians to a lifestyle intervention trial: experiences and lessons from PODOSA (Prevention of Diabetes &#x00026; Obesity in South Asians)</article-title>. <source>Trials</source>
<volume>12</volume>: <fpage>220</fpage>.<pub-id pub-id-type="pmid">21978409</pub-id></mixed-citation></ref><ref id="pone.0057143-Hjellset1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Hjellset</surname><given-names>V</given-names></name>, <name><surname>Bj&#x000f8;rge</surname><given-names>B</given-names></name>, <name><surname>Eriksen</surname><given-names>H</given-names></name>, <name><surname>H&#x000f8;stmark</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>Risk Factors for Type 2 Diabetes Among Female Pakistani Immigrants: The InvaDiab-DEPLAN Study on Pakistani Immigrant Women Living in Oslo, Norway</article-title>. <source>Journal of Immigrant and Minority Health</source>
<volume>13</volume>: <fpage>101</fpage>&#x02013;<lpage>110</lpage>.<pub-id pub-id-type="pmid">19779820</pub-id></mixed-citation></ref><ref id="pone.0057143-Costa1"><label>29</label><mixed-citation publication-type="other">Costa B, Barrio F, Cabr&#x000e9; JJ, Pi&#x000f1;ol JL, Cos X, <etal>et al</etal>.. (2012) Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention. Diabetologia: 1&#x02013;10.</mixed-citation></ref><ref id="pone.0057143-Saito1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Saito</surname><given-names>T</given-names></name>, <name><surname>Watanabe</surname><given-names>M</given-names></name>, <name><surname>Nishida</surname><given-names>J</given-names></name>, <name><surname>Izumi</surname><given-names>T</given-names></name>, <name><surname>Omura</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Lifestyle Modification and Prevention of Type 2 Diabetes in Overweight Japanese With Impaired Fasting Glucose Levels: A Randomized Controlled Trial</article-title>. <source>Arch Intern Med</source>
<volume>171</volume>: <fpage>1352</fpage>&#x02013;<lpage>1360</lpage>.<pub-id pub-id-type="pmid">21824948</pub-id></mixed-citation></ref><ref id="pone.0057143-Absetz1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Absetz</surname><given-names>P</given-names></name>, <name><surname>Oldenburg</surname><given-names>B</given-names></name>, <name><surname>Hankonen</surname><given-names>N</given-names></name>, <name><surname>Valve</surname><given-names>R</given-names></name>, <name><surname>Heinonen</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Type 2 Diabetes Prevention in the Real World</article-title>. <source>Diabetes Care</source>
<volume>32</volume>: <fpage>1418</fpage>&#x02013;<lpage>1420</lpage>.<pub-id pub-id-type="pmid">19401442</pub-id></mixed-citation></ref><ref id="pone.0057143-Penn2"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Penn</surname><given-names>L</given-names></name>, <name><surname>Moffatt</surname><given-names>S</given-names></name>, <name><surname>White</surname><given-names>M</given-names></name> (<year>2008</year>) <article-title>Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study</article-title>. <source>BMC Public Health</source>
<volume>8</volume>: <fpage>235</fpage>.<pub-id pub-id-type="pmid">18616797</pub-id></mixed-citation></ref><ref id="pone.0057143-Ramachandran2"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Ramachandran</surname><given-names>A</given-names></name>, <name><surname>Snehalatha</surname><given-names>C</given-names></name>, <name><surname>Mary</surname><given-names>S</given-names></name>, <name><surname>Mukesh</surname><given-names>B</given-names></name>, <name><surname>Bhaskar</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)</article-title>. <source>Diabetologia</source>
<volume>49</volume>: <fpage>289</fpage>&#x02013;<lpage>297</lpage>.<pub-id pub-id-type="pmid">16391903</pub-id></mixed-citation></ref><ref id="pone.0057143-Douglas2"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Douglas</surname><given-names>N</given-names></name>, <name><surname>Rohini</surname><given-names>M</given-names></name>, <name><surname>Tom</surname><given-names>D</given-names></name>, <name><surname>Catherine</surname><given-names>M</given-names></name>, <name><surname>Trisha</surname><given-names>G</given-names></name> (<year>2011</year>) <article-title>Risk models and scores for type 2 diabetes: systematic review</article-title>. <source>BMJ</source>
<volume>343</volume>: <fpage>d7163</fpage>.<pub-id pub-id-type="pmid">22123912</pub-id></mixed-citation></ref><ref id="pone.0057143-Saaristo2"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Saaristo</surname><given-names>T</given-names></name>, <name><surname>Moilanen</surname><given-names>L</given-names></name>, <name><surname>Korpi-Hy&#x000f6;v&#x000e4;lti</surname><given-names>E</given-names></name>, <name><surname>Vanhala</surname><given-names>M</given-names></name>, <name><surname>Saltevo</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Lifestyle Intervention for Prevention of Type 2 Diabetes in Primary Health Care</article-title>. <source>Diabetes Care</source>
<volume>33</volume>: <fpage>2146</fpage>&#x02013;<lpage>2151</lpage>.<pub-id pub-id-type="pmid">20664020</pub-id></mixed-citation></ref><ref id="pone.0057143-Dombrowski1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Dombrowski</surname><given-names>SU</given-names></name>, <name><surname>Avenell</surname><given-names>A</given-names></name>, <name><surname>Sniehotta</surname><given-names>FF</given-names></name> (<year>2010</year>) <article-title>Behavioural Interventions for Obese Adults with Additional Risk Factors for Morbidity: Systematic Review of Effects on Behaviour, Weight and Disease Risk Factors</article-title>. <source>Obesity Facts: the European journal of obesity</source>
<volume>3</volume>: <fpage>377</fpage>&#x02013;<lpage>396</lpage>.</mixed-citation></ref><ref id="pone.0057143-White1"><label>37</label><mixed-citation publication-type="other">White M, Adams J, Heywood P (2009) How and why do interventions that increase health overall widen inequalities within populations? In: Babones S J, editor. Social inequality and public health. Bristol: The Policy Press.</mixed-citation></ref></ref-list></back></article>